

NON-INSULIN DIABETES PREPARATIONS

© 2015-2022 Y Coleman, Nutrition Consultants Australia

Generic	Duration (hrs)	Time to peak (hr)	Half-life (hr)	Time to steady state (hr)	Terminal phase half-life (hr)	Refs
Biguanides: Increase insulin sensitivity of peripheral tissues. Decreases glucose production by the liver.						
Metformin		2.5	5 6.5 Plasma – 6.2 Blood – 17.6	24-48		1 5 4 4
Metformin XR		2.5	6.5	24-48	6.5	5
Sulfonylureas: Raise serum insulin level by stimulating the beta cells of the pancreas to insulin. Metabolized by cytochrome P450.						
Glibenclamide/Glyburide	15				5-10	5
Gliclazide					10-12	5
Glimepiride	24	2.5	5-8		3-6	2 5
Glipizide	12-24	1-3			2-4	2 5
Dopamine receptor antagonists:						
Bromocriptine		1-3			15	5
A-glycosidase Inhibitors: Delays digestion and absorption of complex carbohydrates. Lowers post-prandial glucose.						
Acarbose (Biphasic)		1.1, 20.7			3.7, 9.6	5
Dipeptidyl Peptidase Inhibitor (DPP-4): Incretins increase insulin release from pancreatic beta cell, and lower glucagon secretion from pancreatic alpha cells.						
Alogliptin		1-2			21	5
Linagliptin (triphasic)		1.5	12	Day 3	100	5
Saxagliptin (biphasic)		2, 4	26.9		2.5, 3.1	5
Sitagliptin		1-4			12.4	5
Vildagliptin		1.7			3	6
Glucagon-like Peptide 1 Agonist (GLP-1): Stimulates glucose-dependent release of insulin and suppresses glucagon levels.						
Exenatide		2	2.4		2.4	7
Dulaglutide		24-72			5 days	8
liraglutide		8-12	13			9
Semaglutide			1 week		1 week	10
Thiazolidinediones: Improves response of peripheral cells. Reduces glucose production by the liver.						
Pioglitazone (biphasic)	24	2	3-7, 16-24			11
SGLT2 inhibitors:						
Dapagliflozin		2			12.9	12
empagliflozin		1.5			12.4	13
ertugliflozin		1		4-6 days	16.6	14
Combination Products: data is available per each drug, and not as a composite product.						

NON-INSULIN DIABETES PREPARATIONS

© 2015-2022 Y Coleman, Nutrition Consultants Australia

References

1. Feingold KR, Anawalt B, Boyce A, et al., Editors. 2022. Oral and Injectable (Non-Insulin) Pharmacological Agents for the Treatment of Type 2 Diabetes. Endotext [Internet]. South Dartmouth. <https://www.ncbi.nlm.nih.gov/books/NBK279141>.
2. Chaudhury A, Duvoor C, Reddy Dendi VS, Kraleti S, Chada A, Ravilla R, Marco A, Shekhawat NS, Montales MT, Kuriakose K, Sasapu A, Beebe A, Patil N, Musham CK, Lohani GP and Mirza W (2017) Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management. *Front. Endocrinol.* 8:6. doi: 10.3389/fendo.2017.00006.
3. Kinaan, M., Ding, H. & Triggler, C.R. 2015. Metformin: An Old Drug for the Treatment of Diabetes but a New Drug for the Protection of the Endothelium. *Medical Principles & Practice* 24:401–415; DOI: 10.1159/000381643.
4. https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/212021bl.pdf
5. emc, 2022. Electronic Medicines Compendium: <https://www.medicines.org.uk/emc/>. Accessed 2022.
6. https://www.ema.europa.eu/en/documents/product-information/galvus-epar-product-information_en.pdf
7. https://www.ema.europa.eu/en/documents/product-information/byetta-epar-product-information_en.pdf
8. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125469s0361bl.pdf
9. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022341s0271bl.pdf
10. https://www.ema.europa.eu/en/documents/product-information/ozempic-epar-product-information_en.pdf
11. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021073s0491bl.pdf
12. https://www.ema.europa.eu/en/documents/product-information/forxiga-epar-product-information_en.pdf
13. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/204629s0081bl.pdf
14. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209803s0041bl.pdf

Calculation for the period drug remain within the body - half-life x 5.5 = x hrs.